Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Patients who develop AML may have detectable mutations years earlier
Desai P et al. Nat Med. 2018;24:1015-23.
Key clinical point: Individuals who develop acute myeloid leukemia may have somatic mutations detectable years before diagnosis.
Major finding: Compared with controls, those who eventually developed AML were more likely to have mutations (odds ratio, 4.86; 95% CI, 3.07-7.77) in baseline assessment at a median of 9.6 years before diagnosis.
Study details: Analysis of blood samples from 212 women who developed AML and 212 age-matched controls in the Women’s Health Initiative.
Disclosures: The researchers reported having no relevant financial disclosures. The WHI program is funded by the National Institutes of Health.
Source: Desai P et al. Nat Med. 2018;24:1015-23.
Desai P et al. Nat Med. 2018;24:1015-23.